- Home
- AAMI vs CDTX Comparison
AAMI vs CDTX Comparison
Compare AAMI & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- CDTX
- Stock Information
- Founded
- AAMI 1980
- CDTX 2012
- Country
- AAMI United States
- CDTX United States
- Employees
- AAMI N/A
- CDTX N/A
- Industry
- AAMI Investment Managers
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AAMI Finance
- CDTX Health Care
- Exchange
- AAMI Nasdaq
- CDTX Nasdaq
- Market Cap
- AAMI 1.6B
- CDTX 1.6B
- IPO Year
- AAMI N/A
- CDTX 2015
- Fundamental
- Price
- AAMI $44.19
- CDTX $100.37
- Analyst Decision
- AAMI Hold
- CDTX Strong Buy
- Analyst Count
- AAMI 3
- CDTX 11
- Target Price
- AAMI $39.67
- CDTX $91.60
- AVG Volume (30 Days)
- AAMI 280.0K
- CDTX 1.2M
- Earning Date
- AAMI 10-30-2025
- CDTX 11-06-2025
- Dividend Yield
- AAMI 0.09%
- CDTX N/A
- EPS Growth
- AAMI 43.58
- CDTX N/A
- EPS
- AAMI 2.41
- CDTX N/A
- Revenue
- AAMI $538,200,000.00
- CDTX N/A
- Revenue This Year
- AAMI $21.37
- CDTX N/A
- Revenue Next Year
- AAMI $16.37
- CDTX N/A
- P/E Ratio
- AAMI $18.50
- CDTX N/A
- Revenue Growth
- AAMI 18.76
- CDTX N/A
- 52 Week Low
- AAMI $22.60
- CDTX $10.14
- 52 Week High
- AAMI $51.65
- CDTX $106.63
- Technical
- Relative Strength Index (RSI)
- AAMI 39.50
- CDTX 73.40
- Support Level
- AAMI $46.88
- CDTX $96.35
- Resistance Level
- AAMI $47.45
- CDTX $106.63
- Average True Range (ATR)
- AAMI 1.52
- CDTX 6.45
- MACD
- AAMI -0.63
- CDTX 1.55
- Stochastic Oscillator
- AAMI 3.78
- CDTX 86.26
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.